Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (508)	2/22/1999 5:31:00 PM
From: Jongmans	Respond to of 4474

I find also names as Xoma, Sheldahl, Geron and Agribiotech (ABT). Not all disasters! Martin

To: Mike McFarland who wrote (508)	2/22/1999 6:39:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 4474

OT: Lotemax is not Alrex Mike, Just to put your Opthamologists comments in perspective, Lotemax is not designed for allergies. Alrex is the drug that PARS markets for allergies! More importantly, Alrex and Lotemax are only cash cows for PARS. The real future for this company is in the pipeline. HU-211 is looking very good. We shall see in the next few months if a major partnership agreement can be cut. If it is, PARS will be off to the races. Obviously, I'm long on PARS. Once, the floorless convertible plays out it should resume upward movement. There's still about 20% of it still outstanding and not yet converted. So, I'm not advocating purchasing PARS at this particular moment. We may not have seen the bottom yet. One of the most striking features of these floorless jobs that I wasn't aware of, but learned from PARS, is that once, the conversion date is past, that's not the end of it. PARS is now over a year since the deal was struck and over 6 months since the conversion date. Yet the pain continues :-( Regards, John de C